Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (521)	2/4/2000 8:42:00 PM
From: Miljenko Zuanic	Read Replies (3) \| Respond to of 666

Biowa, I didn't read any of this patents (only briefly claims), so even if I do have any knowledge on this issue (which I do not) it will be wrong to comment. However, counting what was posted here (from you and many bio-freaks, that I do not miss anyone) it seams that Zev isn't covered by CLTR patents. Regards the dosimetry and early CLTR patent (PB note) one will have to go back and see what were protocols in Zev early safety trials. Nonetheless, moment when Genentech walked away from Zev it was dead for me and no competition to Bexxar at all. Miljenko